Please use this identifier to cite or link to this item:
Title: Survival of patients treated with extended-hours haemodialysis in Europe: an analysis of the ERA-EDTA Registry
Author: Janz, Thijs T.
Noordzij, Marlies
Kramer, Anneke
Laruelle, Eric
Couchoud, Cécile
Collart, Frederic
Cases Amenós, A. (Aleix)
Arici, Mustafa
Helve, Jaako
Waldum-Grevbo, Bård
Rydell, Helena
Traynor, Jamie P.
Zoccali, Carmine
Massy, Ziad A.
Jager, Kitty J.
van Jaarsveld, Brigit C.
Keywords: Hemodiàlisi
Issue Date: 18-Nov-2019
Publisher: Oxford University Press
Abstract: BACKGROUND: Previous US studies have indicated that haemodialysis with ≥6-h sessions [extended-hours haemodialysis (EHD)] may improve patient survival. However, patient characteristics and treatment practices vary between the USA and Europe. We therefore investigated the effect of EHD three times weekly on survival compared with conventional haemodialysis (CHD) among European patients. METHODS: We included patients who were treated with haemodialysis between 2010 and 2017 from eight countries providing data to the European Renal Association-European Dialysis and Transplant Association Registry. Haemodialysis session duration and frequency were recorded once every year or at every change of haemodialysis prescription and were categorized into three groups: CHD (three times weekly, 3.5-4 h/treatment), EHD (three times weekly, ≥6 h/treatment) or other. In the primary analyses we attributed death to the treatment at the time of death and in secondary analyses to EHD if ever initiated. We compared mortality risk for EHD to CHD with causal inference from marginal structural models, using Cox proportional hazards models weighted for the inverse probability of treatment and censoring and adjusted for potential confounders. RESULTS: From a total of 142 460 patients, 1338 patients were ever treated with EHD (three times, 7.1 ± 0.8 h/week) and 89 819 patients were treated exclusively with CHD (three times, 3.9 ± 0.2 h/week). Crude mortality rates were 6.0 and 13.5/100 person-years. In the primary analyses, patients treated with EHD had an adjusted hazard ratio (HR) of 0.73 [95% confidence interval (CI) 0.62-0.85] compared with patients treated with CHD. When we attributed all deaths to EHD after initiation, the HR for EHD was comparable to the primary analyses [HR 0.80 (95% CI 0.71-0.90)]. CONCLUSIONS: EHD is associated with better survival in European patients treated with haemodialysis three times weekly.
Note: Reproducció del document publicat a:
It is part of: Nephrology Dialysis Transplantation, 2019, vol. 35, num. 3, p. 488-495
Related resource:
ISSN: 0931-0509
Appears in Collections:Articles publicats en revistes (Medicina)
Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer)

Files in This Item:
File Description SizeFormat 
696801.pdf354.66 kBAdobe PDFView/Open

This item is licensed under a Creative Commons License Creative Commons